Biovail (BVF) Commences Legal Action Related To ANDAs Filed For Wellbutrin XL
10/19/2005 5:12:31 PM
TORONTO--(BUSINESS WIRE)--Dec. 22, 2004--Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that Biovail Laboratories Inc. has commenced a legal action in its own name, and in the name of SmithKline Beecham Corporation, against two companies that have filed abbreviated new drug applications (ANDAs) with the United States Food and Drug Administration for generic versions of Wellbutrin XL(R) (bupropion hydrochloride extended-release tablets). The formulation for Wellbutrin XL(R) was developed by Biovail. Wellbutrin XL(R) is indicated for the treatment of major depressive disorder in patients aged 18 and older.
comments powered by